Foundayo vs Zepbound
Eli Lilly's Oral Pill vs Its Tirzepatide Injection (2026)
Both Foundayo and Zepbound are Eli Lilly weight-loss drugs — but they sit at opposite ends of the convenience-vs-power trade-off. Foundayo (orforglipron) is a daily oral GLP-1 pill with no fasting. Zepbound (tirzepatide) is a once-weekly dual GLP-1/GIP injection with the higher weight-loss ceiling. Here's how to choose.
Foundayo vs Zepbound: At a Glance
- ✓Non-peptide oral GLP-1 pill (GLP-1 only)
- ✓Once daily — any time, with or without food
- ✓No injection, no fasting, room-temperature storage
- ✓Phase 2 ~14.7% weight loss; ATTAIN-1 up to 27.3 lbs
- ✓Self-pay from ~$149/mo (lowest dose)
- ✓Eli Lilly — FDA approved April 2026
- ✓Dual GLP-1/GIP injectable
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity and sleep apnea
- ✓SURMOUNT-1: ~20.9% weight loss at 72 weeks (15 mg)
- ✓Refrigerated; injection-site rotation needed
- ✓Eli Lilly — widely available now
Detailed Comparison
| Feature | Foundayo (Orforglipron) | Zepbound (Tirzepatide) |
|---|---|---|
| Manufacturer | Eli Lilly | Eli LillyBest |
| Drug Type | Non-peptide small molecule | Peptide dual agonist |
| Mechanism | GLP-1 only | GLP-1 + GIP |
| Administration | Once-daily pill | Once-weekly injection |
| Fasting/Timing | None | N/A (injection) |
| Weight Loss | Phase 2 ~14.7%; up to 27.3 lbs | ~20.9% at 72 weeks (15 mg) |
| Extra Indications | None yet | Obstructive sleep apnea |
| Storage | Room temperature | Refrigerated until use |
| Needles | No | Yes (weekly) |
| FDA Status | Approved April 2026 | Approved (obesity 2023) |
Convenience vs Power
Maximum Weight Loss
Zepbound has the higher ceiling (~20.9% at 72 weeks) thanks to its dual GLP-1/GIP mechanism. If raw efficacy is the priority, the injection leads.
No Needles
Foundayo is a daily pill — no injections, no sharps, no site rotation. For needle-averse patients, that can be decisive.
Travel & Storage
Foundayo is room-temperature; Zepbound needs refrigeration and cold-chain handling. Foundayo wins for travel.
Proven Track Record
Zepbound has multi-year data and a sleep-apnea indication. Foundayo is newer but simpler to take.
Dosing Routine
Foundayo: a pill every day. Zepbound: one injection a week. Pick the rhythm you'll actually keep.
Cost
Foundayo self-pay starts ~$149/mo (lowest dose). Zepbound is pricier without coverage. Check savings cards for both.
Which Should You Choose?
This is a classic convenience-versus-power decision, and both options come from the same company. Zepbound (tirzepatide) is the more powerful drug — its dual GLP-1/GIP mechanism produced about 20.9% weight loss over 72 weeks, and it carries a sleep-apnea indication on top of obesity. The cost is a weekly injection and refrigeration.
Foundayo (orforglipron) trades some of that ceiling for radical simplicity: a daily pill you can take any time, store at room temperature, and travel with easily — and at a lower self-pay entry price. For people who would not start or stick with injections, that trade can be worth it.
A reasonable framing: if you want the most weight loss and don't mind a weekly shot, Zepbound. If you want effective weight loss without needles or refrigeration, Foundayo. Track whichever you start in Shotlee so you can see your real response — and compare cleanly if you ever switch between Lilly's two options.
Foundayo vs Zepbound: Frequently Asked Questions
Zepbound (tirzepatide) has the higher weight-loss ceiling — about 20.9% at 72 weeks (15 mg) thanks to its dual GLP-1/GIP mechanism. Foundayo (orforglipron) showed ~14.7% in Phase 2 (up to 27.3 lbs at higher doses). Zepbound is more powerful; Foundayo is a needle-free pill.
Yes — both are Eli Lilly products. Foundayo is the oral orforglipron pill; Zepbound is the injectable tirzepatide. Lilly offers both an oral and an injectable weight-loss option.
No. Foundayo is a once-daily pill taken any time with or without food. Zepbound is a once-weekly subcutaneous injection that requires refrigeration and injection-site rotation.
Only under medical guidance. People switch for convenience (no needles, room-temperature storage, lower self-pay cost), but Zepbound generally produces more weight loss. Track both in Shotlee to compare your own response.
Yes. Shotlee tracks oral and injectable GLP-1s — dose, weight, and side effects — so you can compare the two on your own data.
Track Foundayo or Zepbound in Shotlee
Free dose logging, weight trends, and side-effect tracking for oral and injectable GLP-1s.